Last reviewed · How we verify
NCT05246228: HR-cSCC
Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
trial testing Peripheral blood sampling in order to evaluate changes in the circulating immune population in Squamous Cell Carcinoma of the Skin in 42 participants. Status unknown.
30 November 2025
Quick facts
| Lead sponsor | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 42 |
| Start date | 1 March 2022 |
| Primary completion | 30 November 2025 |
| Estimated completion | 30 December 2025 |
Drugs / interventions tested
- Peripheral blood sampling in order to evaluate changes in the circulating immune population
Conditions studied
- Squamous Cell Carcinoma of the Skin — all drugs for Squamous Cell Carcinoma of the Skin →
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia — full company profile →
Who can join
18 and older, any sex, with Squamous Cell Carcinoma of the Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Treatment with adjuvant radiotherapy modulates immune system in many diseases as witnessed by dynamic changes of humoral and cellular immunity. Moreover, the persistent lymphopenia after radiation therapy is a negative prognostic factor. This study is aimed to explore the changes in immune-cell populations during radiotherapy given as adjuvant treatment for high-risk cutaneous squamous cell carcinomas and to correlate them with patient's outcome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05246228
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Squamous Cell Carcinoma of the Skin
Currently open trials in the same condition.
- NCT04892849 — Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy · recruiting
Other Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia trials
Trials by the same sponsor.
- NCT06493708 — Effectiveness of EMDR in Borderline Personality Disorder · NA · recruiting
- NCT07370961 — Pilot Study to Evaluate the Impact of a Multidisciplinary Approach (Pharmacological and Psychological) in the Treatment · NA · completed
- NCT05847387 — The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study · recruiting
- NCT05738902 — Adherence and Compliance to ERAS in Gynecological Surgery · unknown
- NCT06765343 — Efficacy of Guided Biofilm Therapy in Pediatric Patient · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05246228 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- Last refreshed: 18 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05246228.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing